Potential Mechanisms of Action of Chinese Patent Medicines for COVID-19: A Review
- 1First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China
- 2Tianjin University of Traditional Chinese Medicine, Tianjin, China
- 3Department of Traditional Chinese Medicine, Hebei North University, Zhangjiakou, China
- 4Department of Cardiology, Traditional Chinese Medicine Hospital of Tianjin Beichen District, Tianjin, China
- 5Tianjin Fourth Central Hospital, Tianjin, China
- 6Shenzhen Hospital Futian of Guangzhou University of Chinese Medicine, Shenzhen, China
- 7Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China
A Corrigendum on
Potential Mechanisms of Action of Chinese Patent Medicines for COVID-19: A Review
by Yang, Z-H., Wang, B., Ma, Q., Wang, L., Lin, Y-X., Yan, H-F., Fan, Z-X., Chen, H-J., Ge, Z., Zhu, F., Wang, H-J., Zhang, B-N., Sun, H-D., and Feng, L-M. (2021). Front. Pharmacol. 12:668407. doi: 10.3389/fphar.2021.668407
Incorrect Affiliation
In the published article, there was an error in affiliation “6”. Instead of “Shenzhen Hospital Futian of Guangzhou University of Chinese Medicine, Tianjin, China”, it should be “Shenzhen Hospital Futian of Guangzhou University of Chinese Medicine, Shenzhen, China”.
We apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: COVID-19, SARS-CoV-2, traditional Chinese medicines, Chinese patent medicines, review
Citation: Yang Z-H, Wang B, Ma Q, Wang L, Lin Y-X, Yan H-F, Fan Z-X, Chen H-J, Ge Z, Zhu F, Wang H-J, Zhang B-N, Sun H-D and Feng L-M (2021) Corrigendum: Potential Mechanisms of Action of Chinese Patent Medicines for COVID-19: A Review. Front. Pharmacol. 12:770125. doi: 10.3389/fphar.2021.770125
Received: 03 September 2021; Accepted: 29 September 2021;
Published: 25 October 2021.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2021 Yang, Wang, Ma, Wang, Lin, Yan, Fan, Chen, Ge, Zhu, Wang, Zhang, Sun and Feng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Li-Min Feng, ZmxpbWludGNtQDE2My5jb20=; Hai-Dong Sun, c2hkMDJAMTYzLmNvbQ==
†These authors have contributed equally to this work and share first authorship